Home

Part of our AI Trading ecosystem

AI Trading Tool

The main AI trading tool page

AI Stock Analysis

4,600+ stocks analyzed

AI Stock Picks

Daily AI-generated picks

AI Stock Picker

Scan the universe for ideas

Stock Recommendations

Ranked AI research ideas

AI Trading Signals

Real-time momentum alerts

AI Stock Screener

Scan 4,600+ stocks live

Best AI Trading Tools

#1 pick: Stockinhood

How AI Trading Works

The technology explained

AI Stock Predictions

Multi-timeframe targets

APMD

Neutral

Apnimed, Inc.

Healthcare·Biotechnology

$28.55

Current Price

1.14B

Market Cap

8.0

P/E Ratio

$35.29

52W High

$16.12

52W Low

Company Profile

CEO

N/A

Employees

N/A

Year Founded

2017

Headquarters

Cambridge, Massachusetts

Sector / Industry

Healthcare · Biotechnology

Key Statistics

Market Cap

1.14B

Today's High

$31.97

Today's Low

$28.39

Open

$31.70

Previous Close

$32.03

52-Week High

$35.29

52-Week Low

$16.12

Today's Volume

433,272

Avg. Volume

615,666

Overnight Volume

4,318

Shares Outstanding

39.82M

P/E Ratio

7.98

EPS

$3.45

Beta

0.00

Dividend Yield

0.00%

Live market stats are a premium feature

These stats are from a cached snapshot. Unlock real-time data with lifetime access — $19.99.

Earnings History

Quarterly expected vs. actual performance

Q2 20262026-08-01
Missed -7%
EPS Est.-0.45
EPS Actual-0.48
Rev. Est.$0.0M
Rev. Actual$0.0M
Q1 20262026-03-31
Beat 9%
EPS Est.-0.35
EPS Actual-0.32
Rev. Est.$0.0M
Rev. Actual$0.0M
Q4 20252025-12-30
Beat 20%
EPS Est.-0.20
EPS Actual-0.16
Rev. Est.$0.0M
Rev. Actual$0.0M
Q3 20252025-09-30
Beat 100%
EPS Est.-0.10
EPS Actual0.00
Rev. Est.$0.0M
Rev. Actual$0.0M

Earnings data is AI-compiled from public sources and may be delayed or approximate. Not financial advice.

Historical Price Chart

Price History

Chart data unavailable

AI Price Targets

Apnimed is a clinical-stage biotech company recently IPO'd in mid-2026. The stock has shown high volatility typical of early-stage pharmaceutical firms. While the company has a promising pipeline for obstructive sleep apnea (AD109), it remains in a high-risk phase with significant cash burn and lack of long-term profitability. Current valuation metrics are inconsistent across sources due to the recent IPO and fluctuating market sentiment. Investors should monitor upcoming clinical trial results and the September 2026 earnings report for clearer guidance.

7-Day Target

$29.50

+0.9%

30-Day Target

$31.00

+2.5%

6-Month Target

$35.00

+6.5%

AI Confidence

65%

Risk Level

High

Analyst Target

$1.5

Bull Case

The successful commercialization of their oral drug delivery platform would disrupt the current injectable-dominated biologic market, offering significantly higher patient convenience and potential for superior safety profiles due to gut-localized activity.

Bear Case

The company faces significant clinical trial execution risks and financial sustainability concerns following recent pipeline setbacks and a narrowed development focus, casting doubt on their ability to reach late-stage commercialization.

Key Catalysts

  • Positive phase 2 clinical trial data readouts
  • Strategic partnerships or licensing agreements for their platform
  • Expansion of the pipeline into new therapeutic indications
  • Regulatory approval milestones for lead candidates

Key Risks

  • •High cash burn rate impacting operational runway
  • •Clinical development failure of lead candidates
  • •Intense competition from established pharmaceutical companies
  • •Regulatory hurdles associated with novel drug delivery platforms

Company Overview

Applied Molecular Transport Inc. (APMD) is a biopharmaceutical company focused on developing oral biologic therapies using its proprietary gut-selective biologic technology platform. The company's lead candidate, AMT-101, is designed to treat inflammatory bowel disease and other autoimmune conditions by targeting the intestinal epithelium.

Take this research further — free

Open APMD in the full AI tools and run your own analysis: live charts, 7-day to 6-month targets, and risk checks. 15 minutes free, no card required.

Rather have it all, permanently?

30-day money-back guarantee • Secure payment by Square

APMD Stock FAQ

What is the AI analysis for APMD stock?

Stockinhood's AI generates multi-timeframe price targets for APMD (Apnimed, Inc.), including 7-day, 30-day, and 6-month outlooks based on market data, technical indicators, and news sentiment. These estimates are for informational purposes only and do not constitute financial advice.

Is APMD stock a good investment?

Our AI assigns a sentiment signal (Bullish, Bearish, or Neutral) to APMD based on multiple factors including price trends, momentum, and market conditions. The current AI signal is Neutral. This is AI-generated research, not financial advice — always consult a licensed advisor before investing.

What is the price target for APMD?

The AI-generated price target for APMD is based on multi-timeframe analysis and represents a hypothetical scenario, not a guarantee. The current price is $28.55. Price targets are educational estimates and should not be relied upon for investment decisions.

What are the risks of investing in APMD?

High cash burn rate impacting operational runway Clinical development failure of lead candidates Intense competition from established pharmaceutical companies Regulatory hurdles associated with novel drug delivery platforms All risk analysis is informational only and not financial advice.

What sector is APMD in?

Apnimed, Inc. (APMD) operates in the Healthcare sector, specifically the Biotechnology industry. This classification helps investors understand the company's business focus and compare it with peers in the same sector.